0001493152-23-005140.txt : 20230215 0001493152-23-005140.hdr.sgml : 20230215 20230215080117 ACCESSION NUMBER: 0001493152-23-005140 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230214 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230215 DATE AS OF CHANGE: 20230215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ocean Biomedical, Inc./DE CENTRAL INDEX KEY: 0001869974 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 871309280 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40793 FILM NUMBER: 23633651 BUSINESS ADDRESS: STREET 1: 515 MADISON AVE SUITE 8078 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 908-2658 MAIL ADDRESS: STREET 1: 515 MADISON AVE SUITE 8078 CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: Aesther Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20210628 8-K 1 form8-k.htm
0001869974 false Ocean Biomedical, Inc./DE 0001869974 2023-02-14 2023-02-14 0001869974 AEHA:CommonStockParValue0.0001PerShareMember 2023-02-14 2023-02-14 0001869974 AEHA:WarrantsEachWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member 2023-02-14 2023-02-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT


Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 14, 2023

 

Ocean Biomedical, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

  

001-40793

  

87-1309280

(State or other jurisdiction

of incorporation)

  

(Commission

File No.)

  

(I.R.S. Employer

Identification No.)

 

55 Claverick St., Room 325
Providence, RI 02903

(Address of Principal Executive Offices)

 

(401) 444-7375

(Registrant’s Telephone Number)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.0001 per share   OCEA   The Nasdaq Stock Market LLC
Warrants, each warrant exercisable for one share of common stock at an exercise price of $11.50  

 

OCEAW

  

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

As announced in a press release and related Current Report on Form 8-K dated August 31, 2022, Aesther Healthcare Acquisition Corp., a Delaware corporation (n/k/a Ocean Biomedical, Inc.) (“ Aesther “), entered into an Agreement and Plan of Merger by and among Aesther, Aesther Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Aesther (“ Merger Sub “), Aesther Healthcare Sponsor, LLC, Aesther’s sponsor, in its capacity as purchaser representative, Ocean Biomedical, Inc., a Delaware corporation (n/k/a Ocean Biomedical Holdings, Inc.) (“ Ocean Biomedical “), and Dr. Chirinjeev Kathuria, in his capacity as seller representative (as may be amended and/or restated from time to time, the “ Merger Agreement “), pursuant to which, among other things, the parties would effect the merger of Merger Sub with and into Ocean Biomedical, with Ocean Biomedical continuing as the surviving entity (the “ Merger “), as a result of which all of the issued and outstanding capital stock of Ocean Biomedical would be exchanged for shares of Class A common stock, par value $0.0001 per share, of Aesther (the “ Share Exchange “), subject to the conditions set forth in the Merger Agreement, with Ocean Biomedical surviving the Share Exchange as a wholly-owned subsidiary of Aesther (the Share Exchange and the other transactions contemplated by the Merger Agreement, together, the “ Transaction “).

 

On February 15, 2023, the Company issued a press release announcing the consummation of the Transaction on February 14, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 is intended to be “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Forward-Looking Statements

 

The information included herein and in any oral statements made in connection herewith include “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics and expectations. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions.

 

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the Company that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include (i) the outcome of any legal proceedings that may be instituted against the Company; (ii) changes in the markets in which the Company competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; (iii) changes in domestic and global general economic conditions; (iv) risk that the Company may not be able to execute its growth strategies; (v) risks related to the ongoing COVID-19 pandemic and response, including supply chain disruptions; (vi) risk that the Company may not be able to develop and maintain effective internal controls; (vii) the risk that the Company may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; (viii) the ability to develop, license or acquire new therapeutics; (ix) the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (x) the risk that the Company experiences difficulties in managing its growth and expanding operations; (xi) the risk of product liability or regulatory lawsuits or proceedings relating to the Company’s business; (xii) the risk of cyber security or foreign exchange losses; (xiii) the risk that the Company is unable to secure or protect its intellectual property

 

2

 

 

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, and which are described in the “Risk Factors” section of the Company’s definitive proxy statement filed by the Company on January 12, 2023, and other documents to be filed by the Company from time to time with the SEC and which are and will be available at www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this filing. Accordingly, undue reliance should not be placed upon the forward-looking statements.

 

Item 9.01. Financial Statements and Exhibits.

 

(a) Not applicable.

 

(b) Not applicable.

 

(c) Not applicable.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press release, dated February 15, 2023.
     
104   Cover Page Interactive Data File (embedded with the Inline XBRL)

 

3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 15, 2023 OCEAN BIOMEDICAL, INC.
   
  By: /s/ Elizabeth Ng
  Name: Elizabeth Ng
  Title: Chief Executive Officer

 

4

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Ocean Biomedical Debuts as Publicly Traded Company Focused on Accelerating the Commercialization of Innovative Assets from Research Universities and Medical Centers

 

Completes business combination with Aesther Healthcare Acquisition Corp.

 

Ocean Biomedical stock will trade on Nasdaq under ticker symbol “OCEA”

 

Providence, RI and New York, NY Feb. 15, 2023 – Ocean Biomedical (“the Company”) (Nasdaq: OCEA), a next-generation biopharma company, today announced the completion of its business combination with Aesther Healthcare Acquisition Corp. (“Aesther”) (Nasdaq: AEHA), a publicly traded special purpose acquisition company. Ocean Biomedical, Inc., the resulting combined company, is expected to commence trading on the Nasdaq Capital Market under the symbol “OCEA” on February 15, 2023. The business combination was approved by Aesther’s shareholders on February 3, 2023. Related transactions included up to a $60 million committed backstop by Vellar Opportunity Fund SPV LLC - Series 3 and a Common Stock Purchase Agreement with White Lion Capital LLC, which provides that White Lion Capital is committed to purchase the Company’s Common Stock with an aggregate gross purchase price of up to $75 million. The arrangement provides Ocean Biomedical access to capital that will enable the company to propel its diversified pipeline to commercial success. The company’s common stock and warrants are expected to be listed on Nasdaq under the symbols “OCEA” and “OCEAW,” respectively.

 

Ocean Will Address Areas of Great Unmet Need Through Novel Scientific Breakthroughs

 

Built on an innovative business model, Ocean Biomedical bridges the ‘bench-to-bedside’ gap by accelerating the commercialization of innovative assets from research universities and medical centers. That involves elevating the efforts of scientists at these institutions to ensure their discoveries advance through discovery to clinical trials, eventually reaching the hands of doctors and patients who need them. Ocean Biomedical’s core portfolio, built from relationships with these leading institutions, is currently focused in three critical areas: oncology, pulmonary fibrosis, and infectious disease. Each include new target discoveries that will enable first-in-class drug and vaccine candidates, developed through past and ongoing grants totaling $123.9 million. All three represent large markets with tremendous unmet medical needs.

 

Oncology

 

●Non-small cell lung cancer (NSCLC) is the leading cause of cancer death and second most diagnosed cancer in the United States, affecting approximately 460,000 people in the U.S. alone.
●Glioblastoma multiforme (GBM) is a lethal type of brain tumor with a single-digit five-year survival rate. It affects approximately 28,000 people in the U.S. alone.

 

Chitinase 3-like-1 (CHI3L1) is a novel target and pathway discovery, the master checkpoint inhibitor, uncovered by the Ocean team. This novel, bispecific antibody approach generates strong anti-tumor response in lung cancer and brain cancer, whether used in combination or as a monotherapy. Ocean Biomedical’s novel approach to tumor suppression, focused on controlling CHI3L1, other immune checkpoint inhibitors, and T-cell co-stimulators, could control important pathways pan-cancer and has potential application for tumor suppression across multiple cancer pathways.

 

 

 

 

 

Pulmonary Fibrosis

 

●Idiopathic pulmonary fibrosis is a progressive disease that results in the irreversible loss of lung function with high morbidity and mortality rates. Its prevalence in the U.S. has been reported to range from 10-60 cases per 100,000 people, while in Europe it ranges from 1.3-32.5 cases per 100,000.
●Hermansky-Pudlak Syndrome (HPS) is a rare genetic disease with high prevalence occurring in Puerto Rico, with 1 case every 1,800 people.

 

Ocean has identified a novel target and pathway discovery called Chitinase 1 (Chit1), as well as a potential inhibitor of this pathway called OCF-203. OCF-203 has been evaluated in multiple models of pulmonary fibrosis with impressive reductions in fibrosis. These discoveries hold potential for growth into other fibrotic diseases, including scleroderma, alcoholic liver disease, and NASH.

 

Malaria

 

●Malaria is a deadly disease with over 3 billion people at risk of infection annually worldwide. 200-300 million people are infected worldwide each year. It is the number one killer of children under five years old, with over 500,000 children under five killed each year.

 

Ocean’s proprietary platform for infectious diseases has yielded promising vaccine and therapeutic candidates for malaria, including the discovery of PfSEA-1 and PfGARP. These targets enable a promising new strategy for combating the disease. Moreover, the company’s drug target discovery platform has the potential to discover targets against other infectious diseases, like tuberculosis or another pandemic-type virus.

 

Notable Investment Activity

 

Ocean and Aesther have partnered with some of the premier investment institutions in the health care space. This has led to a secure and growing runway to continue Ocean’s important innovations, with funding including:

 

●$123.9 million in past and ongoing grants, in use to enable first-in-class drug and vaccine candidates that make up Ocean’s initial core portfolio in oncology, fibrosis, and infectious disease, all based on new target discoveries
●A $60 million committed backstop by Vellar Opportunity Fund SPV LLC – Series 3
●A Common Stock Purchase Agreement with White Lion Capital LLC, which provides that White Lion Capital is committed to purchase the company’s Common Stock with an aggregate gross purchase price of up to $75 million

 

 

 

 

 

Company Leadership

 

Ocean Biomedical will continue to be led by Elizabeth Ng, Chief Executive Officer, a proven biotechnology veteran. Dr. Jack Elias, former Dean of Medicine at Brown University and Professor of Translational Sciences, Medicine, and Molecular Biology at the Warren Alpert Medical School Brown University, and Dr. Jake Kurtis, the current chair of pathology and laboratory medicine at Brown, each Company co-founders, will retain their positions as Scientific Advisory Board Chair and Chief Scientist, respectively. The Ocean executive leadership also includes:

 

●Daniel Behr, Executive Vice President and Head of External Innovation & Academic Partnerships
●Gurinder Kalra, Chief Financial Officer
●Dr. Inderjote Kathuria, Chief Strategy Officer, M.D
●Robert John Sweeney, Chief Accounting Officer
●Kevin Kertscher, Communications Director
●Sharon Talcott, Vice President, Strategic Partnerships

 

Entrepreneur, investor and fellow co-founder Dr. Chirinjeev Kathuria will serve as the Executive Chairman of the Board of Directors. The Board will consist of nine members, including: Suren Ajjarapu, Chairman and CEO of Aesther; Michael Peterson, current member of the Aesther Board of Directors; Martin D. Angle, Independent Director; Dr. Michelle Berry, M.D., M.P.H., Independent Director; Jerome Ringo, Independent Director; and Gov. William Owens, Independent Director.

 

Leadership Commentary

 

“Ocean Biomedical was founded with a singular goal: to discover and advance practice-changing medicine that can address some of the world’s deadliest and most prevalent diseases,” said Dr. Jack Elias, Ocean Biomedical scientific advisory board chair. “Our pipeline, as a result, is currently working on illnesses ranging from lung cancer to malaria, and this is just the beginning – as an emerging biotech, this dexterous and innovative business model is what makes Ocean Biomedical unique. We’re thrilled to be officially trading as a public company, allowing us to advance our pipeline of innovative assets – discovered by our growing world-class network of researchers – and ensuring that these assets can benefit patient outcomes in some of the most devastating illnesses we face as humans today.”

 

“Ocean Biomedical is a category of one as the parent company of three biopharma companies, each with individual assets that will change the practice of medicine,” said Dr. Chirinjeev Kathuria, Ocean Biomedical Chairman of the Board of Directors. “Our highly experienced management team – with scientific, clinical, and commercial expertise at the top levels of the industry – has primed each to eventually bring a number of innovative treatments to market. Ocean also has the potential to leverage the current core portfolio into additional disease indications through existing and new partnerships with premier research institutions. With this milestone, we’re ready and excited to execute further on our goal of getting drugs to patients, working with leading experts to accelerate the development of innovative therapies, and providing new models for academic partnerships. We believe our work will change the course of humanity, making the world better through better medical interventions and treatments.”

 

“We’re immensely excited that Ocean Biomedical has completed the transition to be a publicly-traded company. We’re confident that the combination of the company’s unique business model and cutting-edge science will deliver lasting value to investors while advancing our abilities to treat difficult diseases,” said Suren Ajjarapu, Chairman and CEO of Aesther. “I’m personally confident that this transaction will buttress Ocean’s long-term mission to champion paradigm shifting science and deliver it to the world.”

 

 

 

 

 

Advisors

 

Cohen & Company Capital Markets serves as lead capital markets advisor along with EF Hutton, division of Benchmark Investments, LLC to Aesther Healthcare Acquisition Corp. Nelson Mullins Riley & Scarborough LLP serves as legal counsel to Aesther Healthcare Acquisition Corp. and Malone Bailey, LLP serves as auditors to Aesther Healthcare Acquisition Corp. Dykema Gossett PLLC serves as legal counsel to Ocean Biomedical, Inc. and Deloitte & Touche LLP serves as auditors to Ocean Biomedical, Inc.

 

About Aesther Healthcare Acquisition Corp.

 

Aesther is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Its principals possess public and private market investing experience and operational knowledge to bring value added benefits to Ocean Biomedical. The Aesther team has substantial experience investing in and operating businesses in multiple sectors, as well as a significant long-term track record in creatively structuring transactions to unlock and maximize value.

 

To learn more, visit www.aestherhealthcarespac.com.

 

About Ocean Biomedical

 

Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic, to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most.

 

To learn more, visit www.oceanbiomedical.com

 

Forward-Looking Statements

 

This press release contains certain statements that are not historical facts and are forward-looking statements within the meaning of the federal securities laws with respect to the proposed merger agreement between Aesther and Ocean Biomedical (the “Transaction”), including without limitation statements regarding the anticipated benefits of the proposed Transaction, the anticipated timing of the proposed Transaction, the implied enterprise value, future financial condition and performance of Ocean Biomedical and the combined company after the closing and expected financial impacts of the proposed Transaction, the satisfaction of closing conditions to the proposed Transaction, the level of redemptions of Aesther’s public stockholders and the products and markets and expected future performance and market opportunities of Ocean Biomedical. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “think,” “strategy,” “future,” “opportunity,” “potential,” “plan,” “seeks,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.

 

 

 

 

 

The announcement today is based solely on laboratory and animal studies. Ocean Biomedical has not conducted any studies that show similar efficacy or safety in humans. There can be no assurances that this treatment will prove safe or effective in humans, and that any clinical benefits of this treatment is subject to clinical trials and ultimate approval of its use in patients by the FDA. Such approval, if granted, could be years away.

 

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (i) the risk that the proposed Transaction may not be completed in a timely manner or at all, which may adversely affect the price of Aesther’s securities; (ii) the risk that the proposed Transaction may not be completed by Aesther’s business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the proposed Transaction, including the approval of the Merger Agreement by the stockholders of Aesther, the satisfaction of the minimum net tangible assets and minimum cash at closing requirements and the receipt of certain governmental, regulatory and third party approvals; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (v) the failure to achieve the minimum amount of cash available following any redemptions by Aesther’s stockholders; (vi) redemptions exceeding anticipated levels or the failure to meet The Nasdaq Capital Market’s initial listing standards in connection with the consummation of the proposed Transaction; (vii) the effect of the announcement or pendency of the proposed Transaction on Ocean Biomedical’s business relationships, operating results, and business generally; (viii) risks that the proposed Transaction disrupts current plans and operations of Ocean Biomedical; (ix) the outcome of any legal proceedings that may be instituted against Ocean Biomedical or against Aesther related to the Merger Agreement or the proposed Transaction ; (x) changes in the markets in which Ocean Biomedical’s competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; (xi) changes in domestic and global general economic conditions; (xii) risk that Ocean Biomedical may not be able to execute its growth strategies; (xiii) risks related to the ongoing COVID-19 pandemic and response, including supply chain disruptions; (xiv) risk that Ocean Biomedical may not be able to develop and maintain effective internal controls; (xv) costs related to the proposed Transaction and the failure to realize anticipated benefits of the proposed Transaction or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions; (xvi) the ability to recognize the anticipated benefits of the proposed Transaction and to achieve its commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Ocean Biomedical to grow and manage growth economically and hire and retain key employees; (xvii) the risk that Ocean Biomedical may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; (xviii) the ability to develop, license or acquire new therapeutics; (xix) the risk that Ocean Biomedical will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (xx) the risk that Ocean Biomedical, post-combination, experiences difficulties in managing its growth and expanding operations; (xxi) the risk of product liability or regulatory lawsuits or proceedings relating to Ocean Biomedical’s business; (xxii) the risk of cyber security or foreign exchange losses; (xxiii) the risk that Ocean Biomedical is unable to secure or protect its intellectual property; and (xxiv) those factors discussed in Aesther’s filings with the SEC and that that will be contained in the proxy statement relating to the proposed Transaction .

 

 

 

 

 

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that will be described in the “Risk Factors” section of the preliminary proxy statement and the amendments thereto, the definitive proxy statement, and other documents to be filed by Aesther from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and while Ocean Biomedical and Aesther may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Neither of Ocean Biomedical or Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations. These forward-looking statements should not be relied upon as representing Aesther’s or Ocean Biomedical’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

 

Additional Information and Where to Find It

 

In connection with the Merger Agreement and the proposed Transaction, Aesther intends to file with the U.S. Securities and Exchange Commission (the “SEC”) a proxy statement on Schedule 14A relating to the proposed Transaction. This communication is not intended to be, and is not, a substitute for the proxy statement or any other document that Aesther has filed or may file with the SEC in connection with the proposed Transaction. Aesther’s stockholders and other interested persons are advised to read, when available, the preliminary proxy statement and the amendments thereto, the definitive proxy statement and documents incorporated by reference therein filed in connection with the proposed Transaction, as these materials will contain important information about Aesther, Ocean Biomedical, the Merger Agreement, and the proposed Transaction. When available, the definitive proxy statement and other relevant materials for the proposed Transaction will be mailed to stockholders of Aesther as of a record date to be established for voting on the proposed Transaction. Before making any voting or investment decision, investors and stockholders of Aesther are urged to carefully read the entire proxy statement, when they become available, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, because they will contain important information about the proposed Transaction. Aesther investors and stockholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement, and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to: Aesther Healthcare Acquisition Corp., 515 Madison Avenue, Suite 8078, New York, NY 10022, Attention: Mr. Suren Ajjarapu.

 

Participants in Solicitation

 

Aesther, Ocean Biomedical and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Aesther’s stockholders with respect to the proposed Transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed Transaction of Aesther’s directors and officers in Aesther’s filings with the SEC, including, when filed with the SEC, the preliminary proxy statement and the amendments thereto, the definitive proxy statement, and other documents filed with the SEC. Such information with respect to Ocean Biomedical’s directors and executive officers will also be included in the proxy statement.

 

 

 

 

 

No Offer or Solicitation

 

This press release is not a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Transaction and will not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

Investor Contact

 

Email: IR@aestherhealthcarespac.com

 

Media Contact

 

Sean Leous
ICR Westwicke
Phone: +1.646.866.4012
Email: Sean.Leous@westwicke.com

 

 

 

 GRAPHIC 3 ex99-1.jpg begin 644 ex99-1.jpg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end EX-101.SCH 4 aeha-20230214.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 aeha-20230214_def.xml XBRL DEFINITION FILE EX-101.LAB 6 aeha-20230214_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common stock, par value $0.0001 per share Warrants, each warrant exercisable for one share of common stock at an exercise price of $11.50 Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 aeha-20230214_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Feb. 14, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 14, 2023
Entity File Number 001-40793
Entity Registrant Name Ocean Biomedical, Inc./DE
Entity Central Index Key 0001869974
Entity Tax Identification Number 87-1309280
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 55 Claverick St.
Entity Address, Address Line Two Room 325
Entity Address, City or Town Providence
Entity Address, State or Province RI
Entity Address, Postal Zip Code 02903
City Area Code (401)
Local Phone Number 444-7375
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common stock, par value $0.0001 per share  
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol OCEA
Security Exchange Name NASDAQ
Warrants, each warrant exercisable for one share of common stock at an exercise price of $11.50  
Title of 12(b) Security Warrants, each warrant exercisable for one share of common stock at an exercise price of $11.50
Trading Symbol OCEAW
Security Exchange Name NASDAQ
XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001869974 2023-02-14 2023-02-14 0001869974 AEHA:CommonStockParValue0.0001PerShareMember 2023-02-14 2023-02-14 0001869974 AEHA:WarrantsEachWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member 2023-02-14 2023-02-14 iso4217:USD shares iso4217:USD shares 0001869974 false Ocean Biomedical, Inc./DE 8-K 2023-02-14 DE 001-40793 87-1309280 55 Claverick St. Room 325 Providence RI 02903 (401) 444-7375 false false false false Common stock, par value $0.0001 per share OCEA NASDAQ Warrants, each warrant exercisable for one share of common stock at an exercise price of $11.50 OCEAW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://aestherhealthcarespac.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - form8-k.htm 22 form8-k.htm aeha-20230214.xsd aeha-20230214_def.xml aeha-20230214_lab.xml aeha-20230214_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 27 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "aeha-20230214_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "aeha-20230214_lab.xml" ] }, "presentationLink": { "local": [ "aeha-20230214_pre.xml" ] }, "schema": { "local": [ "aeha-20230214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 2, "memberStandard": 0, "nsprefix": "AEHA", "nsuri": "http://aestherhealthcarespac.com/20230214", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-02-14to2023-02-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://aestherhealthcarespac.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-02-14to2023-02-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "AEHA_CommonStockParValue0.0001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.0001 per share" } } }, "localname": "CommonStockParValue0.0001PerShareMember", "nsuri": "http://aestherhealthcarespac.com/20230214", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "domainItemType" }, "AEHA_WarrantsEachWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each warrant exercisable for one share of common stock at an exercise price of $11.50" } } }, "localname": "WarrantsEachWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member", "nsuri": "http://aestherhealthcarespac.com/20230214", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001493152-23-005140-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-005140-xbrl.zip M4$L#!!0 ( "= 3U:=PW"%% 0 !D0 1 865H82TR,#(S,#(Q-"YX M__4KP:;^R;7+)( I:I"M\N\?'XBWY1&-HD0_ 05(MY%MR1Z/4 MS(A+%H$DYR).(M" "[FE%CFI>6]&Q+8/T+T#'@CY^::WT VU3E3+<6:S68V+ M1SH3+-&3H A@W3.!=XX%F%!Q\J'1A(-9*(! MC!EGF>7B6'K$-H(YOM_.9N%(9+"2K]+96M*P5%1 )2,\S_E7LC=YUI0Q^LF"'& MCK*(\S-"CNBH:LA(@>@%8[TR^C\U2,RDJD&N)]\+1=I=&%D-M[@BGFS2YYMIFRO;C>\VEP%2T^K.+'&JM" M=CY5V9?-YN$P/\H^ GTH!(ZUCR&L=AD_\#TRF4H?Y/NMRW/N?(^9O:NC#H0O M4J[E4Y5#L4HI7X[+S&5_6"T/\H]@4N%8LT=DP;;Q9U.@Z"6S;LPTHM_P;RT6 M?*B%/QU0F?WGN#73A@U #D-LYOH0CTS_9KPV'=RA;O94?="D1,&>]IB T2=R$=*:Q*J4%_D"+%UC^78PC9 M%]P]E9)RK2ZH'Q;CBSE(GRGC&C;4UQPRKZ_'*X&=E2 82.;CFN?53MSU?7@1 MY?]WR]I.GETX_ ]02P,$% @ )T!/5NE7.)8>"0 %FD !4 !A96AA M+3(P,C,P,C$T7V1E9BYX;6S575M3XS@:?=^J_0_>['/(A69FFVEV*IT.,ZGI M;EC"=,_L"Z782J)"D5*2#,F_'\F78,?Z;(;NF MW@,6DG!VT1F<]#L>9CX/"%M>='Z?=4>S\73:\:1"+$"4,WS18;SS\W__^0]/ M_WSX5[?K71),@W/O$_>[4[;@/WE?T1J?>[]@A@527/SD?4,T-&?X):%8>&.^ MWE"LL/XB+OC<.SL9_#CWNMT:^7[#+.#B]YOI/M^54AMYWNL]/CZ>,/Z 'KFX MER<^7]?+<*:0"N4^M_ZVG_S$R3]0PN[/S:\YDMC3>C%YOI7DHF/*38I]/#WA M8MD;]ON#WA]?/L_\%5ZC+F%&-Q]WTE0F%UNZP?OW[WO1MRFT@-S.!4W+..VE M=/8YZV\#M4^0!9_UXB^S4%*2=8:T).(5W4\+0_'+PS!?T[!U*[C6[0DICVV/%Z.1)(^"D/&SA; M"E#E5'E3U[.H\)7.0OCA''<#LL;,M/V.EQ24K>@^%\)43T-[":9GS>#U>>\+ MZP9\CKW/^F..-]XJ/0CA(&5N,GQ6)Z6(,BF3\6;@=%FIZ9BZ*&,JW\ LEYI$ HNTN$-EK-X;"'J9+I&=-! M#B--DQ-W9DC$AH:N.I[J0YD60-$EO4MFC\UJQ+&">Z0[9/S M(Y'R3II-S6LS;JOG/F=*MY4)C4K3[1TOS4'*;"'XNE+*1#9>6H.LMII(Q^,B MP$+/Y_I/7"B7.+CH*!%:JNS8H#%%4EXM9HK[]Z,MJ=.ZBDE>U#;KP%IE4UY] MP"*HKA:WWLJ7+,5/R1 -&6+#OJ@3Q=E"E0V@PKR2.63%L-].+^X&%N(O94CU#5G4>G72$3!8?_$C-+76,Q6>ES_ MDDP0"^Z8Y#53OX)?^=DKX$7)M<"?5PFP4WMNKP;8\AT)@9B2$^2ODN/)5G?= M1)K.^)*+*X8C;E>+#/U1"L+7@OCZN\'@Y*Q?ZN#+%W1GZU4:8_8KU1?L85]D MM)/8/UGRAUZ 2=RYZH.G/E5_N$LGU+(6F;[J-.T(=3]AZ0NR49DI*2!R!MD.K0\)@YV% MV[[B!B^)5"*ZY;FO4'GG84W2:!.JF8,S+;=NC!@+$;W!&RXJ3,@B6Z%]@3 D M^3NWDO\O1$)A07=U5#\ MT)X&V=(^S/'$Q4]\Y*15'7$/T2W0GTK:4C^']S* M/UMA2LT32L1JM?XBOA46 +0A$WY\.Q,F#V:BH*M6WX=]DM99D6<.N?$?MV[H M:)_P0-=)U/#A -P*!VR<(>W?OX7V$Q;453Z!MDCW+..R!QDN9;\DTDI MS]F>4&0J4H"W0GX[ZQ>_D?>W+/@3(U';@#VX1?+G.8/B.XJ QZ$0.6JE/0^$ M;K3\I:1!_1W%O!.FB-J997)?0^#>M(8=HAJMMY4LJ+.C0#(3EF M[_A79GH!] 6J&YC#,KN*+"-F5T+LD9B M-R-^=<=RB&V!\%;*H/*.HMF8VBW:3@-=";(@\2+::@. )"WPH8PY:(>C<#9F M.&4^%QN>N=\]YJ&^:G=C'I0. :4)6V!--7_0($9\&PE18,RRUP%/]"[$Z/L^"TE1:+I0YRJ(D>W1/DL8U-QIF)P0N^92(?I_LJF:G=KP[=&_2!MTP5'4G+0( M0**BMHSCW,S=/=5:YA_W6CE<$E\KQ)9?=#T$0=2N>1'7:,$!NJ#:CJ++:X%-&\!Z MDA\MAC-;B<758@'UU#"^T>I7T 9=HVK-57+]O45R]K]-6.(LV45+Q07U]W5W-*E@C>$5B2H!7J0[PA(VQU>@TC MXOU:YN5Q8AVQNM0'=@NLT$:+#S,&97>U%38,B,)!3/"2,,1\'E#TF19^7[DBM\J6J:^/44+3"@A#GKA].'IE"DL MD*_( _Z$%$KXEGEA3]$"+TJ(@UXX77@<7:AC79\E+U\[D .V0/DB7U!PI^N- M9VM$Z<=0Z@K(TOXG!VR!X$6^H.!.5Q1/UE@L=3?XB^"/:I5LY"T3WIJ@!0; MO$$CG*X.M\V.?-\L-8GG!"Q G QC?: M@PK:H N.PN0K\][A[*PLHF8J4[80I"I5HQVI11[TQ6F8G'W-0^FPG,$U6GN M+JBVTRCX.IQ3XE]2CDKG_1E8"[0^9 M*[33R_8C8O0@WRM]="^YC;!X,R?TU M62/XJI5!"^RI7P_0.+=;<9]>XQF]V%->A2KZ1R^:;>F-BY)T+;"IDC[HCN-7 M4Q MMYYU;#=RDK8[G0Q$01+'%* !*5O^]\4'29$@#DD["8!<) KY'N %\1 /P"^ M_F6W3M #X6G,Z)O!^/!H@ B-V#RFRS>#C]/AZ?3L\G* T@S3.4X8)6\&E U^ M^?F/?T#BS^L_#8?H(B;)_ 2]8]'PDB[83^@:K\D)^I50PG'&^$_H$TZV<@N[ MB!/"T1E;;Q*2$;%#9WR"?CP<_V.&AL,>Z7XB=,[XQP^79;JK+-ND)Z/1X^/C M(64/^)'Q^_0P8NM^"4XSG&W3,K6CW5'^1X>_3F)Z?R+_FN&4('&\:'JR2^,W M YEOGNWC\2'CR]'DZ&@\^O?[JVFT(FL\C*D\;A$9%%$R%5O<^-6K5R.UMY V ME+L93XH\CD>%G3)EL3=NT5> MCP]WZ7Q0''QU!#E+R >R0*J8)]G31J"4QI*$0;YMQU=+*@T:NS=X2'K/Y.7V9:S/:DWUQ M[O#L*PI0C7=>A#N6X>1%YJN1SFU?DY<=\7V<^R,MVGGRLB-=B?PNMK.FY63&*_&K9I'L,M&!D7EA4B;1T@*K'%3'D*==ILZB6KJ);,T9;Y9=]HPJ MS05.9RKA;3I<8KP1&4PF(Y)D:;%E*+>H@Y!O^"+[1K(F-#M+<)K>+*89B^Y/ M=W%:Y*,*^6;00S\R"R C3WE1"LRCCD.1*T81$QW9)ALF^J#K\ 5GZUXV\F/& M>HB_)+,R?7V0A06@(#49)RG;\H@\JXZKI>E[5'.'ZT1$R $;H<./T\'/2H;8 M BDA^EU*__=ZM$_Z)2QALL(2D..CR?AO"I+3\W^>?A&#N36C*J-;S-48ZNA0 M#)[&HH&?KC G[\EZ1KA1LN>%ND#G)861%#TGSCM0+S#;8$M%BPL"$7Z -IBC M!YD"^D&G@39B@)_*5+X3;Y\QYYAFZ3F.5OGO\QWA49SB64(N&+^A1)7B9E$I MZ&DA(K<\CL2^\?CPQR,8S>^1BS.*O]\A*H'_]EF$<6Y\MW*9IU&1T0$B(BOT MJ/^+R#XSM& 1DBU Q:QP5*X9W/5ELF7J4(_:YD7]W[?SL@Q(B87(J?G4/(BM +& VC M5CA*57B F-9:()%2I+3?EI241(=+]C":DUA#(G[LV1#_^?*.15M%LTC1*%!S MMPL.(%.R]LU]WNL<,&36="%!4N.X@D]%QG.9^46"EQ;[QGY756RU5=1Q;6<0 ME6QS9-9RJ4%2Y*N:WY$TXO%&WEEN*T=-YKS2+28;=5_1A(5 TQA,0D7KJ6'_ M0)9QFG'UJ*'L<5J:,4#ONNEOM6WV!59Q$-#T<0CV%M4@5$9YXNB4TBU./I - MXVWXU&6NJ;&9-&&I:H)BQ&(,1$-KD19[(N)?6\PSPI.G3B@:2M=< %9-- Q9 M4'38O8& E'*_C-QQ3--8-F"=D#2ESB\W +.-2P]#%Q0G@#GXDJ34^R5ENB)) M(E]-P;2[0;&)7=,"&S9Y:2J#(@:T!S*C(E >$@XVYP]R="Z&23T+6]'[A*=A MNXV?4APL0J;#GA2I,"3C/)%4>2.F@Z&&TC4]@%63&T,6%#%V;R K6HZ4WC\D MYW3>"Y%2YP<0PZ8=CUP4(!QU9UUH"+5/,"[B-,*)]G(AMIF/5SJTK@$![9J0 M-(1!@0*Y V'1 04S*L0K,/\AF/?#I:+T TO#JAV54A8@**:W+DRDW@LD9UO. M:Z[A'@>6NL*DRVS!":0+ I0.JGYXBD!S>1\&K XILPM 7:3=0KJFH!(L!H# M:-AKU?0F+T2;S&_&D:1QU=15/H%@W(:)T-4Q40'( U@(Y4JP203,$+<:?SN3A0:?[/ M54S)&"R_5>N6KA:[=:8LPH!(@MT!_.3*@^('DC'HAH8"S>0919WXAV;2%YI) MT-!,7@+-W2,+!)KC9Q3UV#\TQWVA.0X:FN,702,JWFM;D&F:=4*S%X6'BX-;UVPR YGI$A/C%1 ZL;?LO90TPC>,@,R;T YBV4F-H MPT/';K"+GW) 7,1Y;6OTH+SS)"ED?EJ9NDE[$Z,UX4%2-];9N&BU3R1N69KA MY+_QIO5"W"[V@H?5L!62FC(\5&SVNH#1,4@$^;BPSG&5#S2L4\F,_-MML ME8^8JSN#@,#FJ+FFA[Y[HD6NJUDRR@D&6H3Z;F>5;#%5UG%E7QA5W#34J&%U M7@N-CQ-9+C28W*X8A5\0:$I;H;+Q<[2^W- M=V6?LY[=M%-VY,6.(&K7=-/HIHO]CFOS,X\SD;-<^&9+\Z<\MO<& 9VK6FZU M6=2X511$[;?/,:V4ME$KH" #18T-!5! MH #::JSD4@I1H70,P2TG$D(B*D)- I1K7/*;Q<+:V[>)74'1;;B U8& 4FG M/1,6$3",*A%(AR 5XQ>;RS3=$OXL>"PAGA "S0,@-?0AX@29[(1*!_ID:TJB MK>@?G\:3V5V<-1:ALTN<]4F N;)',O8'P09@RF1![9-K$8XG?YG]%151CJO_ MFMUQ++]C,'U:SU@"K#YE5;F"H,5BP8%%$@0*L"^3AFN&U[!X$++T- I8=@X!EB(. 9=]!P-+;(*#(5B\1(MJE MFUD2+S&P.&&KVC44+99-/BS2H%"!_8%M1AF"]C&N5[142YS)+T7QM\.<49+3_,E.!WZ,!CJ9[*!DPXKUC(L _=+7;J^E:Y?P/A,DN0WRA[I ME."443+7]U)L3XK:]6[?F.FP77]I!A '@5,?A\"K,S)H>"^C4!&6WPGS0M(G MEFQIAKF:2\YM+1.@IEAFA.,HBQ_(.YSAW!M87DCN M>E)EFVES-J5-&Q!"K0;!^9-EC%PJ!A=,>5LRAI^)H=:2M;PE;JC<+QS3L-A< M.Z:4!(2'S5?+"C(<%5HO+$S7.$G>;M.8DA3NB R56Q:L%NLLU"0!L6#S!;"@ MI*C0>F'A?$WX4G1OOW+VF*WR]5G!L@%JMVRT6JXS8I4&Q$J;/X"9(@3IF&)) M73_P[/8+BNM5%N&26J2.L0'-&LPT="$! YEKT)*02-YON689NF/H8TI0MB+H M//\B)V.KR^-1)&<$*%'Y72.N0VA-K'SKXZ AAO?'FDH@P"ITQ[\'9(R M A4ACJFY$0SSZG6<,B&_I0?.=N@.<4507_,%1UWZ(&CJ:=)D2H75+ZY5H/HN MHL_5C*J+V\-#O)K(\,:]ISU@L;R\(B("F*VB)/"5$2NFE_M]B>L^WFRQZNN4L(D2^9966K577 M_;>>T6Z9>5:1ZC3U"@V(L^?X!0C<)X$J:1Q4>BR?-_,JGT-7'TA/;[99*GM0 M80R^"]X:Y/CQ0H\"& \96B("0J^'3>B!@_[@O H]0#H85:(]79^E^U4 R?SM MTP>R(%S..[@CN^RMR.B^Y0JC1ZSKJ[?>Q3$OYCH#@X#PN6ZA2[T451- ,_F. M6)X$^ETF@E0JMN^75S==B5]B<[%)_#7#*1%;_@]02P,$% @ )T!/5L$R MJ+!H" L&, !4 !A96AA+3(P,C,P,C$T7W!R92YX;6S575USVS86?>_, M_@=6?=:GFVWCQMM1%*O5-(F\EIMT]R4#D9"$,01H -"6_OT"E"A+(@%>M8TN M-P\.31X0]YP#@K@D0+_Y>;WDT1-5FDEQT^BV.HV(BE@F3,QO&K]/FOW)8#1J M1-H0D1 N!;UI"-GX^5__^":R_]Y\VVQ&0T9Y&V@/;BJ^C5ZWN#].HV02<]Q,5B52_WX_V MYUT8L]+7[?;S\W-+R"?R+-6C;L5R"3OAQ!"3ZOW9.NO.[M^V^!O.Q..U^S$E MFD96+Z&OUYK=-%R]NVJ?KUI2S=N]3J?;_N/#^TF\H$O29,+I%M-&7LJ=I:Q< M]_7KU^WL: XM(-=3Q?,ZKMIY./LSVZ,L@#^(1+-KG87W7L;$9+975A-Y$>ZW M9@YKNEW-;J]YU6VM==+(Q<\45)+3>SJ+W/_6O7VMA&JSH&I!"3>+F"BJ5R1V M[K4=LCV0MG7:L+-S+!2=W30(71!;5>^JT^M^[RKZ[@AD-BO;2C5SC:P1M8^" M6-G34V$RWN_MCJ,B=&ULVZ))?B)7_Y\*TS#C2NZ:43=JNC:7+FW%=G.+W$65 MQ\5E?!0*=][($]YY.\\53.Z',.M'KN0TG2B\3Q/[R):NH/]5&D=CD M9^)D2GEV_B\6\Q+C;\<5=?]2)\T"F MSK%"H#O@*>XTVD-O^^HX(=HKZ[(PS7C!^+Y-S)1<^N3; M52B#44N54&5[VDX'76][ ="1W=0 S0^PR+I[= V+?Q#^SH!>#0P8<*+U>#8Q M,G[LKQG$AV*1_T<[BBSVEP66*8Q'^U39PYF,P'L _VC.5CR6,$T)ZO MY8Y_C).[4X@81=:^K3]Q,0PYF9?K>@(!"MM%5;:4%I:T[ZB.%5LY@2H4/D)B MWTG.$[J$)%(/<4_GS&5$+I0]AW"7X2F"W<6?U8D$:2-9T1KJ2J<. 8 M"13^^UH(7T822>]_IT09JO@&(GD!#%3]52U4]U#%&I78@95F3BB(\D4T4/I_ MUD)Z'UDD[2<+RKE[I$\$J-V7X8'Z_U +_?V$:^# [9,;#%@V"ZX65'Z1*'043 M['#\:*CVN*EM%=L+BW\K##,;-X7D8^IYV&QA1114;-QTUL<.1>3\888P;HI, M2.A3)%1LW"PVQ!)%\($-6!$^$@E=_T8W(<4+4*CDN-EKD">*YG>*+8G:3%A< MW9\4L5#5<7/6,%,4V1_(>I38L-F,;>>?5:OO+0(U 3=A!?%&\6(D8JE6\N"I M]4"F]@K=#&02[/8K"D)]PI#/GM?G7C!4>]PL MMX(KIO)9_&-UI^03VT[>KY*_4 +J01V2WS!KU$M@.R* M/\<"16^#HEP.4M, MP>^D-H3_EZVJ!J+E>*CX=4B)0XPO_7ASVP#<EM756 M*TK\#?H8 546-[4M8W5A8=]+]U)F(47PL7 1!148-T?UL;MTY^R6QFEOKW!P M&#QI#[?K/>5S83T_*V9L!&[.=RIVSX,\+_ \4*C.N(EED.>%-9](SF)FF)A_ ML)$K1GBYX&4XJ-JX::2?X86EOE/464[M\#V;L>:6U:KQ;.;KG4-XJ/2X660U M8UP+1EJG5)UK1$DIJ!VX"264_:6[(!JGMD?<='O3![=&W-,!%5!0T7&321^[ M"XO\43XHXCY@,=DLIY+[5]:4 J%2XZ:. 8X75OLHCG*=3R!0A7%SQE)>2-W% M[3I>$#&G_LD8Y4BHTK@Y9(@E6O\\!_7/\S/[9]Q3MW'E[C8VGG,V) M?WU>L !XK5(MI ]POO3RR&S9E/L.DEIF<0SM1KG^'BA4>>2EJ"&>E]8\39BA MR3:D(1-$Q#9'V]/P/ "H+@5U GFM*I ]RGN'SY3SWX1\%A-*M!0TV:8,H5%!PK5O@[O.ST\<2:@;N=Z[^]/VX_B MA:3WE8 Z4(<7GV'62%/R#'6?$V-/]!TQ9!=AR A?":@1=7@)&F:-MM! #2R# MN0R_^3\!0F6OP\3@4HXH:D^6A/.WJ;8AZV"WSFA6QO^R(ARB-_" \UH!X+6/V,+VS!V'U*]W#4E07CP@_-X:@N!;4#-Q&& MLL>Y$1]\52%X'S["086O0\I;QA!G 5HZY2P>W"D94^K>Z^C]]0?(L( G@'I3A\SW+$UPGDB\? \S^T*F'JVHL?P4 I0'&I4 M/;X)!=:CQ*\W[0)!6^6C/;H[XGZX/Z]@]_P/4$L#!!0 ( "= 3U;;G\,E MN"8 %37 * 97@Y.2TQ+FAT;>U]:W/;1M+N=U;Q/\S)NR?EU*%HR8Z= MQ/:Z7MUL:]<7E:0DE8]#8$B.!0((!J#$_?6GG^X9 +Q(%FW+MKQ,U:Y%$ICI MZ>GI>_<\>W7VYO7S;N?9J\/= _I7X;]G9T=GKP^?/[LO_]*O]_W/S_;>'?RE M3L_^>GWXSQ^&65H^43O;>:G.[,0X]=9?-%3IZ:PPQ_H17KU>-WW MGJJ)+D8V?:+P:/V_'Y[_F Y<_O39_>.%@4MS66[IQ([HE<*.QN53]X MP8 K(&VC*#)I:8KU<;159CFOH/YBD)5E-N'O/N=:GAV]>:E.3_;_^8.Y_.VW MK9W^^WST@]I]??;/'^C'JY9X=S;CLR+^J5K>V\^Z&7O/WT5&I]W.GLTF)K:1 M3M2!&52E4]JIXVJ0V"B9J;-"QR96^]DDU^E,OF9@BL@3S?^A;>B0;JJ,TS:;T:6K4KG.&1A\6V42=&&=T$8W5[RG]5#A; M6N.Z'9W&ZHT'9I_7[.2(W@YQW#:2ORN".7H.(DA,B8T:5,ZFQCD599.!366[ M+VPY5KO&$3$4ZI7123F.=$$;'_U=66PQ/;.?%7E?/;M_=&[/Q;\YQ?5*^UP]NUO\Q=?Q>_/CXML:F.31J;7[9P<*?!8#/!75ISW MU-N_GMW__;DB<4 +?F$&?;7SJ*<>;#]XJ'Y,8^W&?OU[SQ63B&I1R#V_YY[Y M0T#XK?])W1-2>:) $#_UE%8I5CHR*8N,C&AM8+-\K(N)!A/!RSU59K&>$81I M5A&\,8N52+B.ER>6),@G,I\ MG\X@-SMU##O'KX2F/,@!DL1@RXWD&_T?9%G MSBC=&MPOHK^$IQX)P:C?X\44QE4)2TR!G<:L%V^=,ISF!G\8QCXQB2ZQD85.G8XPK%,VC9(*Z*QR MVG%"\S\>;RNB[\2C<6)+O#/0T3DQH9QF[G;^,$FB"_4NS[.BK%);DBY"2U:G MQW^HUZ_WU18? 3H;#YG -6LC--PI<['CBG0-31NV.RJ,(:R60B]_CFUIU&NF M#8].&JRG+L:6=)-<3HXCK.I2GNUVYAZVK@4O+24/\\P="8^M.8AX>B(3/2*( M1H0C-2HRPG\]0EY8VGJB>$'2/WYY%%#$.T8;4Q!.1[*8&M*E,ZI)2Z-A04X> M9EX,LW63ZD%BZD,&_0YK*++<)'S08M'-AI96EUOZEFA$! =3-5W7[ LBK%G^"Y';CN ][A:&K RB[I?T1TE6 MP(18V%M#VW\V+K)J-%9OB>DDZC2R1-]$@9':HR?/2_G506A]X2V]RDWQK1/0 M7F63LMNA8T6,1&Q M)-'Q5+/X]109?F,N&1$O9)C*@E9'Z#=3FJK2"2D+1*C1.( SI@4P,'$6E5DA M"\H)7 ,V>#'.2#%B@3\VDV7=H<5)"4;(OF%&,J!'NT>[&O"6,&[=V.9.!(LL M-3&B-[27S&I&5!4%34^@#KT];Z%:D&CL=J*"\,Z2 T?T";'C*$NR$>DG>940 M,X=X']H!"2M+@V$Q-AV"S685! 9MH3-]=4@8"'*>%GBA2J)].N)M_"X)HJ$M M7+E%ID^4$%UT.W%1C7B&*1$61$]$'VQ,PI)FC@GA"4FJN-Z?7+N2'\_2489U MCT34E!F)/7S^QPZI)+\U8G07I@U632C,07TD21/ B9-Z#KH$,FEK"DC9& NL MF%$%>L3.N>]6M'SKX+_SE'EG%[ :_V>[>Z\/U?[AZ]?'NP<'1V]?_O.'[1_X M\^GQ[G[X[.>_L'$YQGC;__<3/+^TJ+.3];%&YYA914 1#8?@P+.S@_7'\@O9 M[C]X9%.X@\\.GG^6@3[?;OW/;X]_^:W9KH\%\):)ZFV6;KD)R2$?_;GA?R2X M$Y54,$PA] HRX$_W7^__!'$!,19D2:1)7D"<^<=B4M_&S'6=B3+(ZLR!S>M1 MFD&PR&/KP6+%SOV=K#P:X;04AJ^'+&8(!C9)+^V$OB<1]O/C[=[V]K;*398G MIGZY?]I7.LE2TY_;L?MG)TRB7Y7!J(65P M8M2]EWMOF)8U43(I'B3X9SG3\:#0()EJDA7>*%>D%X\2LQ7;D245BW31K1DI MIHK4Q*F=TJNDX)K^>J *E_X. 6&D&>H:^[$*^N];+_IC4 MT91TRF[GX59BS\W6CKJW_^KHX>L=OY\I&XI>O_3*]?A"SQI]75QO$R(A8EC1 MV$3G.>F'," X$IP5/45F:I7RT^+IP@NBBY=&3_KL(ST;6U)*>3K2ORW[ F&8 MDI)I!UD\DYV%XNN]G+105Q89.!8]LB4T!J\$Z>&\UVU^"\B%%N4+.*$,.S.# M@MYRS9$952!,IXG=IAF>TOD*SV-M/0B.:OC(?A%@7)5#\74T9*^V!=@)EQ+@ M"6O-@NR>XFF4G4PJ:.(U%KN=&HW>'CC;8F$295M$#70&M?P49542AY%I'!@S M&KXKV2Y'?Y#FWR!C3.O+LQ(&G&;8$UH2^R7I2"_#W^WHB#UH?.IQF/Q88?PO MK:=_X1,7YOD_6UOJA35)_$0=ZY%Y2H/]7<&-3'.JK2V?%/+LX.B/E;QC10#J M,;X;9$5LBOJ[O41'YVJG_XA /N\94I M%*N\=6T"F9NQM8'WL8.R:7>'7C\FDGE]9LA7@.BNBLOCX*/I=EYX)\W&/-Z8 MQQOS.(!Y%-L,&H&-UE/@EYV?HGV21C5B#61J@O=3')L2Z75!I;=%8=BI#4=G M CV%; _H?^N!,20MM0EWC^UH3!I@,; Q J+L*H=6E> 3*Z!]LCQ(C:*Y=<*Q MY+:% 0UK8$P*]R>]!B_T.K"0%LD12/%"[VQO/=XFGP0H!1D6G%;WOG_T[_X=;#!_U',L*:>]-,]PT:^YO#^]G ?&4*>LR=S[:. MJSC1Y^N1R>DLC8G4C+KWZOC4&X\%XM PUVBSZ_/;G*W6P&KP,"MX%^K"#]!^G+F#(LIW=6**UN0L.3H+$U$&,_K>[IZ\VD;"O!/X;G>C"ZCL+_T;3WR@+MW4HU@P]@=?'1L?);%X= M %-5#]7 9REZ?SWT?.O..3'59T$@S2:5/)"+K$ABV@;35P^VM[<>;F^O&;]8 MF*PP?A:2'_78"LDF"@$*Z/HA7)=6DP$!G*5&G=,HAH551"IX7)AT/2@D"P]A M$)Z%Y%02]UI(>>05_3!Z^P6>.VZ!N-%O/E:_";[\;@<)FB3@2Z@)>:)+1+A8 MN"\GXCA6/6;P)B*%D[1?B^!6G5 #R2W1 U-!!V@2;'C B1RAMD8 XJK5)\[F M.AZ>'NYN[?!8Q\.7NR?'01D1SNTLU3JLP0E",DNWTRAU-5*P>+S7Z$"D]H3G:O#T2"-#*@0XEI'84P@\ MJ;*B(Q55":MEB+](Y 5QB]A,;+2%D&*W,[5%=4VPX1-)^]:H^#,G?;[-2FQZ MMW.43HTK.4MY%\FXMIS=9O+FY\#/BN/\!9#FK1@\9<#:&X',+E.C)]CF7R\4@D_5HC?0-ID)@> M1H*%9ZJH4M@UG/%-YR>M?%"T/H!-%"_D='**(0,Z)#D@YK+G'4_N;HWG%U=% M5X7P-ZKI]Z*:2B+JQRF#=*:O2'2%F$:R@.*DYA49M>J:A-HU7;_P<$\T"<4J M]RSA?WY]L/,+6$)J6=+.)RP#M":3^$/YP[WUH"%E6PVT3UU8G6R\<0M_Q\>) MU(W=]2CF@P5GZD/U9DSO.T_KJK,YG69#9!LB4Y]2@0AJNK8*<1TX;EZQ&.RK MP,NOKUA<#XH;ES?>T$7PB3ICGZCXR[H)KIGQ)LE;#S;)6YODK2]"M]]> M<: M)VE3=UN+*U]_WNV\-AH5^F.;;\IFUW7'M.IAN52Q=H3XFG5)%S]$?>O D(!\ M.^HAFFR&ZO#21!47N;X;#BUG=+,'=&I2-;!9::)QRO80Z7MTB'3:5P=%7_T+ MO)G&TPX9V<7$%.J (2%9R:V1V&];JKTBNTB;]DF2_7-<9$/CG,2FS]!S04I# MM:^DCK#B,(I87V^RA."$KDM+97"D5%;]J5$DJG:3G#AUZ,K4[9Q&XRQ+EJ:7 MP60!9!;^NR+N[KS75JI-%0E^RX A7NZGHG<23>($.>(SJ:MLKZ\GH8/0?2K* MMH89AQ<]INS;WUWQ)^W?B\OF?[Z4"GI!>M M9S/LF3%QS8:1_@&;X9C.**?Y\ E^1<<1/.7PDG@H^-Q1[8A6/^H)Z92[D>;P M#&G4[$CG,OF-J?X=D]K+JK 0$NL1V[]U4N@@O%_85*?U:Z7O3/]@0SW=,/"?9@+9E/?KY5S9.U>F% M,:F9!9VC4SL?Y-^^BB,9@*/+-5Z@MBG3JPA4%W MH0W%?,<4=>X%.?4AM?A6?.]?VW?WK8-_F);$?2XD04CE?6_,M%9(Q%WE3,%=UM@1TQA2[ $A M4$(BD?A%Z$-@)+Z?HWR/D;J=B!B-19K<4*7PT4P,4DS;Y0)/U&G%+J/W[W6A M\ZK7S,/.EL-W>-DG-SU5;VPTUB91QW!_.70@")XB&3H %[*A&!CV@]50/D7W M4Q*9ZJ"O=M&TH\>J66Y2-A##K,@6:0I!BUL?_'_=?]:]Z[U^& M*X9.:'79W#/=3O,0%O+?#S>I3 MY-!^!9_X9E,"^+YQZ[*O72,#&0PN;G?E83_U*-/)D[E,7N[XZ[LUY@7:#$=F MBYA+.H(V77N5.8 >@1OY+J3M7$I.J&^2K+D&P!J?:,5-K4(Q8-DD!H,E[O]10TS4>:1T\T@/FL.P:[]=];*NB;K=+_)_KSZ2<>*%[(\%\[AM#$^=! M,T_"?N&7S66U[0XSA+$ZH5L2OZ6(&?O**!B0/I"F>->W_N;2MU29B0%QC+AE M-^(6/7DW-G"Z(6]+TKBN:"V*.2Y"PMB*%L6DQ_Y=&>*>H9TH=^,LI'1 PBP9 M#"++116^&;9'BS3H;GIH:TA'K*#BGL>!*+(61M7*#J1AQ8&F)*Z#]WPVK!"( M3Z1+30G6ZP,E=1T<-'MN^ 8)"EQ]+;VOB<2]!$UA78"+<$.;2Y@.HW-+J8(V3TJ2 MI/UOT[=WP,=5U\53EE M4_S'^I@C*09D):%HB-J:>#:\^9O@S7^VZ=W"%'"&>92G=_#0);Z'$^YO(_%W MD_"U%G+]AR@JS94A6_[*D/I:D+9Z0[;T4&*803F ?=W!X(M !F017H9 M5AW.^^;0?F7;?0'P:])D'V[29#=ILG?O1'WEZ]^^PL6<=VV'OCC/VWONTQ:_ MX!68=SYK=S\;H[^%9'Z%M-'YF]* UU52Y$W"H#RO)KKO1;71OR6BA#V\J=%MVZH14L9G/ M7#NE5TB&L(E! F<.[A&76%906Z&J7#\5W-V8B_-]N:^XVM.8J+SYPV3UH2S)+_XLJR+2OZZ&;_50 M=_:\?P?L:I!5Y5-&?I'@@EF;I<$OY-XAM MF>8F#077/A)* A.4J_K(#F:72$^MV./!-*^9 TGQ4CG=:W/A?*65JL M+JZYJ1,\"!UFX H+3S7M2BT9HKE.T >7[O@YQ>OCYUR]:'P:V_'UCZEQIC+ MN^35I4E2;A"L:)OJ3=^8\1!&P8YE<"_XRD(:D?1@ M593JXN*BKX74QC7_1,^6/IV@N[M7)!W"=GUQQG\;,FZ11UR[K$\N%41?@E&! M:#A\"5GQ!!Z[TEPMTU8V,/ID[%X)QBT6W7G]D&5?ZR)K=3+.8J..7$(<;4MZ M?RQ=)UU7K%\=F6;O8A-_<,L!B/FH4RWBAJT@E7=93G(C%Z9\Y)V62^[FV.1) M-G/B'0[=E"0J$T)?B$1E4W_#XNH^;H9#Y_ZV1X#$MWDU-7?>SREQMMZ\VW,) M)M9"FOP#CRG.-@!VF_YN2_<\.MUEIVS"LGW[K%'8R/=/A,%\P5BW,D;E_9RC!_UY&@_27*@X$IF5Z/= M2RJ,?AW[C$MFX]@ 0@+X'X(2."'.SH9W*!-$?0 MSAJ[Q,?4?NJ%$NJ0(T#LGP3"Q)8B:UOK0=^9HFY#"N,+9F+9-N#JSH@>Y-:$ MO:6W2IJEA9.K7[*3/$%/>9;59( Z;ST1DZ]*M$T]VE@;A#!N\71 !37)YK8GKUE%8;["SJP!]Z(V_^=H/CQ[V7@\*7M>Y MU0E66]@33- MA'!WM^._IY6\)XCK,+C_6M:Q^&U#>4O/XZ*\%=\CD22-%[_%F3Y? B5TTUU\ M6E"Y^&V#P:47:@5MZ0=2MA>_<\:N",/[22NBGT$&?& M,3N>\-V0S* ;JH+:B!\7R*[?[;RXFA!!?@0 T:WOGNJ)JDX>DB[#[3=@A(8S MPFIN2U;4C1!#MID0H_87WK/4<*X*1Y<^]]1B6&X;Y=/SJ:<4Q&#TTY@T]%:@581RJ,+T:@<5DN%%"VG&JGW07/ M"8M3;F#%8V%,'TF:FF;8X(*!.$++)I^_W>W,J^AS(UO7ECCA%7K (@;$LB<1 M#4GN,)Y*SC$&J^0FY9!M'+2W%P>[?75:1>/ZA9ZR0VF4;.(>LBTKSN/U=UKH M"SW[ED3:7:9^W-5]C>(M^@Z[#XO79CV%/@^\/6O07:=W] -P::V3CGC7BB[MF?^,#Q-3@AF7FE$4KPS/PN M<;*S3Z-&E!2&.%@B$5B*TH("-1T$>&B!BS=U#/\YGM+,=/P\OJ1ET?QLW!I/ M"<1K89PSA/!'EWBCAF-5KY.V<"F;E1L9@I>&0\!'HA7(.=$%DTZE],'T1*)^B M$=^GY^,HG,YOBLE""KX@L]NIL4D 3)=V-L0QVDC3$[1SX>4R>J;TN#3EST*1 M(F!N^U%6T%E[T\BRO378H;+9Y2$@MB_J /JM3(R_"6](D;JQVO7D +C+,1?#U[BZTK MJKPD&SM8WG"8N/E4E)7>*M#TI:=I"7T%@I8$.IK.;[(+-R_,P*!"71?T0'^' MT7+ #LS4_QB\M(P.$:0K^46(6ZU:)<%*H,H)JR^8"3X\^B@,>Q&,)D[&<=+2 MM-M&+/F1UDZIIIIEE3"#[.BS3P\<(#4SH$:(ZA8XN9G MON4F(6F>A,U6AB@XFW M<>#,/(+?_2M*@EKB0GO!'@KEL I_W:;WS5D/5$U1 M*+6;VXIPH5YPFOV=8D6,,^O2'LA! / MO(_H>L^LY=C$G);ONRS"YU9DS(XO:98H^*L)!Z\ I\!2%JM]P M*L*)$R<\_4P"WWB(F>[.#9WR"9(@C/&8MC\!#/,AL@9U8>9S8W*%&Z_\UI*T MBQL>XK,L:@Q*W:J8)IQ2L=#6H!VWZ'9@@UAH^GQ1WKEI9P2V;N1BSE.1<(SH M63>L$JG:;8= PDA^B=RZD;@@DI(,N\+-:1'(LH*$;@L(SP5K+ 8'2DO-26 MI5JY1[ 'C!T'L M(?NSW&HIV+U6BJ=KK"OK$RI!71RZ;K%>'U;2DCW3R&&&H&T7H"^U; IAN2;H M.<&" &G%9[>8D\FB7D ;7\X>;21?P)W,O#!U-$/%N;=:>%[X0\G\KU-Q5<*I ML/[M)8MF:7\MRD4#6_>7NV4%!SE+L#?+E%FB(9*8D>!$I)?/)#B"65C/1]P>>]!D&37\Y:5G<;I5>R MR6_)8?-U8Q"/-C&(30QB$X/8Q"#:,0A0LY@3B>_;%_BX#U.;R['&JJ:FK_[* M*B4Q>KXGE/04J<-'OTCO1:B'"\,$75Z\+%<$BGT)?V#]L7%1800 M9"]DX+JI@(GFW0D&GD=.^%R4%P$439_BD#UE2(_,>CZG-[AV60*VW^VU@NQQ M%E6U)CA 6D\RY_[SCE1"/@LF_-L6=W7:B1>%GFZM0K$-?V5,WY M>ULNYV#>7.?TS5Q+X :L+[B!4=,3_,!]=4VR IE&^MS[YFL;)O:M6R259J)Q MX?F)]-KC;PAZ["/-#JKC2\=*6&.5N.LE.2J]#B;9(^E3L3*'*NP/E'^3>#]" ME0?(KD\%0M@,3I>[4S6F("2V6Z9@=.4+(\\"3G10%X%>Y(C@5 MN(K$:UDV08PVX_W>/^T3$'7>,88[#%8N^K)*VYYNIYTX3-(U) S+-5ISXA^7 M5$9C$UWK8\]X4>2Q"5#!W MF5RZ)E.:V!]X= M1,*;!57:.'1ZBSK8DB*UAA*V4G]KE"^;$H/-D1HCLI-JU1'I28CAZJWZ+,1N MS!0P-HL87A.O\;>D#;!HZ_NI7A$'#C(Q5!>+[L1J,#U 8%HW]AD;TZSTE5%7 MKW"/K6DEK?. CEG]6M%RC]*J(^ZGT6LU)&.GZ%50TJ 589N7TI@J(%D)*I)F M4"QA4*C9*W,#PS&V%OHE^VJVB..&(H7>VF=SOEP;NE-#]-LMPGTW_ UOH0L:ZVIY81 MV+@$@8P/G_E>71Q"HJ) ;X*,*_U;NUB&L6L6>&$&#ARQZ M_\J*<_KK+WBF'CP@Z5B64I;X1+TI^@LM\^YN@?<=+\8GI1+78'"4CJTM.A"G M&=E2O@CI-K7(+^M^NH76)+WE>OB@"MBB=:.F/V[9W;.C^U<@K^Q4^1:1>G:"K@YEGLT MSVI#\,8/A 8EL\!=N<])C+"FZ"T-7Y^O:4OUQ(1VZJ*EU4D6JR/@RZEO-9:% M#WOT,F)N$K)IQ<.]"KA*]GV"/TX"N)\N/WQ^;QN7BUMWI2N@QI'H:;^)/F_C3G>TC\W6;;^Y]* YVMSOF?!]]?]ZB=R$' M6,ARV&B&']/IP+O6]))JYMUY/0XW!M]91:9>$3+=%N4Z5STU#D1V*-2_+R36 MS:?WU]46OHPJN/'X,HNA7)+C8-1[G\H2K*WG!M5L 9(>#5O(^*SML)V-)S1L M;30-:H#F[G!>B> EO*=?7*@";E)I'90VQ[LCFWO[ O$S M _R&C"<]3XI[)W<"^+MSZ$]AJ+XV6>6 6Z+S_1/U)Q'ZA8W.C7QU/,Y2>O[_ M[?0?__RX_^OCQ_V?MW<>R&]R/!1&Z?,H_WL17K[=DW$'6,<:ET?\\E2]D[S^ M)^JU=N7&JEW;JKUU&_/V^ !!P0 "P &9OYW M!;5Y$P8"#%R\Z#O_ZZ)=EQ$H>!6<)CAMVM!6P] MNEO]5DO>^K]!UR(]Y@GNV)]3A6P^19AM.":WVY]3@=_*K*?^;WMQ8:OC0SMH M:XO/J8[ONQNY7+_?S_97LH[7SA7*Y7)N@&U2JM'&(+%=,9\OY+X?'S6,#NO2 M#+>%3VV#19TL;M_-'A_?1DV;GL7'FN*3<)*5W-30\-8<=8@W_I13+\>:^HE- M5U53/VS*A5,J%M8>@D.UB#H,9K4M(,R (?N^M47+\;K4 MAS7$D58S^6*F^"DV2$8P8VP@^#O;=GJ_'&<]LU((QYE:G'%,\763BHCB)IL@ M=S@GO( >Q6+8T&.MF<-^RL';L&$@,FU*W:AQBXJF;*A?C(VJGV5$X+H6ZS+; MG]D/V\B^/U?"WL+S'^RIWT_T@O$\QV(B<2;Y9@Q$T_)W#U]@G MG\D7,L5H*0PGL'UOF$Q?_7)L*H W$8FQ1I6]+Y6H%67"[S"OPZCE=PSJ,>%2 M(VLX7>RRDB\62BFI%Q@UX2?!?[9\[EML>RNG?L+;+O,IP0$S[&? >Y]354SP9^3JF/'/;+Z6&W_BN3(37.+'.#-)B_24YHEVV0@3G8 M)/5=^<&\;Z9B>]-B.\3!BW5HEZ_ MTWVU>L- 2@ 9^&_/!G(.JT GCUIUVV2#0S:\R8,F7?]4+J\]:=QR;-P*<+:) MW%VS:/NF12W!GC)4;0K$<];F K6(CQUN3@U&;;+#G2XSN4&M-*G;1C:WN_>$ M63[ATN[>%&ZT&E73P:.GC%&\:71P/6^*-])JJ$&$?/:4<781EC,]ULH42#,' M;SKFD A_:+'/J19P_ 8IY%V?7/ N-#EA?7+N=*F=5@_2 (#'6U*V3-X+^YE< MN!8=;A#;L9E\R0<;*"3,0^F3?W'39+:41?P3&IX$71C+4&(V\,]1S]8\IXL< MB2:B4/*=T>\I8@/6,!7C&XD\E]H>,=U6;FR*YYEUC"-3VY(EYS)1$K^FMF:#U AU=MB-29)$3Z/GW,0W M+C?5 M#=AI1J?PS2188P"$#S5)'TOGT6\W1B!\L"!5I]MU[(;O&'=GU/M&K8#ELTBN M,^9)?7+,NDWFO=JBC.C,VBA_L1?ZE0G #%R+&]Q7L!(3M)6MH@;M1FTT?" I M]J]:5(C3ED2X,N BM8TF=N.19-C*);9MPGT& 2QJ118Y/N,MOI*!0Y^; M?@<'R/\G-?:BZ7BP&!G?<3?(CD6-.U("Q(1C<7.3Z)=-QP<+$[X'=3=J$0&%GGL>R;!#5DAEJ\#0\,T.YH5I\%YG6)?7/[\J1^L;>[ MN-"XJ%SL-;::G@P7&GO5R_/Z17VO02HGNV3O>_5+Y61_CU1/CX_KC4;]]&0K MUYSBI#>+;%$C>T5%A]MMW['3BPN[V6J6%/.KI?*[PN4],UOM]/P8X)1#HH'$ MC$@YKW) FA9X(D 8@+B.]#< MP-T04E@AI^>DL+ID+A.G1?P.BQ0N,P*/^QQFVQL8'6J#C:L8/K8JE%=*[X\2 M[Y$%,7997 "2GS/7\7RRA ]P"1@%QY0)G[ >3$H\^9J9RQL$%WQ"G94GU-F9 M#'[V5&B4K-=\<[W2,TK62?7VM_6:VG/[G.(#?\/$R!7Z=4PZ' +PS$[2>V. MI;9KK.D%U!N20BE-<.0/=?BZUE(.IO+)BPN3">5WNQA+>P-J^(L+F"TG4M;" M_#FA@C1<9F VQR3<)G5?D"J$F@#!\OM"4D,;,IZ&VR\/'!Y&PF,QQ/%CQLD,"&F!?+(5)3EF%-6P:U<012['BN M[B>3C56UY5YUS!EVHG!RV+L<-ML]WW@..X'U')CH\YGK.3TT$..&XA%P@M%D M%NV#B9EI+9+TU%;.-Z>9ZP&608X)I2FIZP=?_@N^K([Q98U;#!:QR;QD)FQ^ MO? .?5-TU\O/$(1-SHDY_D*FE%\KS_8_DBV?Y(@77;P/1GYCC%P<8^0+.JCK MW2%#]GV(JR\KS"X?FA_]Y;]FYB//[ M&+;3N((/*LT8<3SB8+46N8786X!SC6LT(O2S_?,$R, AYG%[N_P4)3,_S?(T MZN)V)Q?BU8F)5H6<.-EW2<1Z]CS;R)*]KFLY0]P;?DU*CJNQ<9J.-$-.!CC; M;SXZ>^9\P-LPER,K6!JS@A73])@0^L<1V,U"L@6T+WYXIVO7@Q_W*\]F 1,F M3VVOKBXN5"W:PY'O2,//SC"":3*)V=XO,"LF8W;5\E>ZKM'\GO\T1\R*J>US MQ^F"\[4ZRZKK9._#_K<>L@J_GGH73M].1JK:;#6#:OVV;1>>&ZG1U*GM,X@, ML<;&F!7@3:_26A(ZTN*>>G(X&"P9I_NCSK=/YZ6#5NWNN7&:F!_6JCX#H2E\ M/B7A<^9 X&S]X.[L:'W'#G97CAH'["=_;FS&9H>0J5C.OTBZ]E55W9)&7J;H MSSQ81NY2B^P-F!'XO,?(:0LL%!/O+%?XAUNC72T]J%0J'J.SY65_;;W'&Q73 MMI[# ,7G ]XIY0O+,R1D]H[TD0,QRUG'L1],B-2ZWX(?@\OC3O\YX)Z<,[5= M*I4R:RMK,ZW*GR/@H[V __WO]6)A;1-D_8)9S$5R$$6/#^E^3>D^R56P\.Z/ MX;B:XX$PA;M1'E%_$VUITH2W< ?*;C.3--!O($=4^'I_^)DY\0US7<):W 8" M L+A%X M"$1?(=(G@WL'QJ,R<0UI ("%E%:RA[Z@Y.$W!0D:RJPB#>:!-2IA<7 M%Z@]#%^V' MFQXZX3<(QKR'(DF",[#.;>>""U&WH'*@:CTJVF%7P+F^\-P:9 M_P9E5!1J %&I*P"@\+I 4RWZ> M=./8*&\+O4GA6='"TW#D$1=0*L>@Y4'56\F2TV+^M\/*];['GF7/>Z;D3,/S M?L1F!+L"IZLQF):90HEF"L68V(Q5&T9"4\IG50^V.&3E9 MO(Q^CW?::LV*3H<]:U ZNR@8QNIC^>!E;89G2DO$X M&=-M9\C8<^U2OO5X_5D=C,BY7EQ0L3+S(-IVD\XX2%6H0V=8FH\@^$T%P8\[ MD_DDE%;6_S/O/-T%7@6E<)'',8P.,?!4_H/:32]7A*O$\M&%>',@5#$_?T)Y MU(S"@,:PVW2L);'\OLCT OR$Z=YQ=F*A-0$5UN]P>#+2@=W80WXV5FWJ5QH^\?R60>>:W+S7WY=KUT?WCM'=X]I5+S]Z_3 MB><()K!.;:M!U H*'"I-7.J1'HY&_D>-1UR\V:3S4(U\,]E/FVX_=RBS\T M&]]J[;K]Y>"%],/DB1HT)=.':9*H O:ZH^W0"14F_4GD=.28>G?,)T='U4?R MSE]NE7;G9I6>_Y*GF_O:T8\J=4];_?VGW&+P(E=V/6CKPOG2BC6DV]17S\!] MBB9&>2!8KR%-'CI8AIQ=V4="?0)KI]LSXB(0V.A_)!ROHBO_S5F9ERJ\"/%\ MU@,AKUT3]LS^P3R$M>1=[71*P\.+Z^(;%M8$K^/J<>5B'^+TYXC3?!RO>4B5 M7:@>-,[Y;K[V]J3JM=VY=WNL)OG2@S=>=%:W\5(-O/>E.20&5J#A]'>DWV'R M:.!$=1@7TGN!U6MC05C;<_I^!QT<%PO&J" F:W%;75^ABE3RJV$R?*)"15WM MLT*6D&!KF[)0);\JB]O]#LP#?.7BS1=8EJCV0(K-3#%AL*0+@Z)1<3]DU"\V M;/:]Y>7?#GQ[>OD7%R;6_^'S2F&W?=FIJOHD;RM>WY<;!]\/C:#X^Q>=)6PK M^E[ IL^4),*E-Q0_S=Y0?*NK\RYK7^LM+#F=I5C2H$Z4FB+C6HI/E:]V0 ; MP44$K[JR*EEFA,6OBK5OWM?UWS\0]YBM^%E0_7H+_F^2F#DX%O.ZL?:!&VEG MW&$;W7'[<6/M8Q0E4!&H!BHML$W<\W:\#=QC\]ESQT4)YU)BBX'+L G]?P98 M>P+]U)K(F&^:01[8T?S5P95/$IY1'4&\;F"RKF!\TNF"@(G"@6FT1PG?A#3N M^')8K"5[F(E",EFQ%<8=X37;4W3R&+W+-!GH3(#&E<2-4^93\I&>Z5L0].-1 MW# V8UR:GE&07I519V0?WC=2=9]U%Q?6LOD"WND76+*4B]1VR2X7AN7@%?'9 M/PGE%U2?\B&X@ R'S&=7N?T"&#XP146@MVK#&T.%NA1\/R8$.(K@,H&["1XA M_D[1"ZT&GH>WINI+59$GP@-FTW#G.'5+Q?PF>?0M4QJ<\'H MW7\Y360&11( _%P8J]+VF$RF2?S/+"K/EQV#2P_(@...3VG700];CSG"5;=J M!$T%:!P_$D=/#@(+ ?9AF''ZF&L005-PD^/=K3!?..+3$1W!,(5K!'%\41JN M8PL'D#@ZJD:8A"=WB0C? G]P7Q"#HMGS998$ @0( 3#T (Y!VA&\0A_>L:R M/7FUR1?'0ILK?G_9)X><7G].:1^)_ XE5C+=(O&&@0& M2 +&?PIGL@1ONG1(FB W716AP<@Y&7?)VQDA\(*8A?@@K1A1X<^T#*-^=X4C M1IW&*0S=%A=@)ED(E58\JZ_*\CN*JCB]2SV9@.H[@642UFI!J"=?=-4T(^8' MEB(ZJ-3B,KW.\OWD8UQL##,#C#2!3C@Z6)(>[^$#];D;LO0O:)&PJ@*8#2@? M6#*;IHK!J&6%L2O'VFNY1,0)?!G](BRPT-Q'@-4V)S2>XDE%IR:+BLU4X*T_ M\P<]9!*>5,8V3!\L*$J/"7R,#.&=!H^@@\R/1Q'Y-#U N]S*A74D^K >)E=5 MVH+YB L&S [OIMDKQF+&EM!F1=[5FH%%_E?G9 ? MGP$,32OP;"XZ.#UN"71XD_ND7,X6E.!"B]F.6)96D\'ZBR\]+&/U2<3NLWBM,DM-9> MQHK'D1I=U\A,N8D4?6,S] N'6AOIVP=F'EG6&T+* BE\)+B3"=,TV@_FROO2 MV4 R MYS$"GC)C@;0MVC;HQ! ^BB*=. O(PZ^K-4SPOEL1YK;$!^P2,V,T>. M67[7E/G33IA(,VM^LA0_Q48)U37VXK8R05WPZN1U*JVXJR1HBQ%P MRIJ.%W:*79NBVU[:'+TPR:X"[W+KX=Y63!\>P0]]1>N8Y:#0F M'V,>U* B>A[91V4V)YOWN65-/@-MGC P1&,",RMHPV'UN!'X"W+;^"(Z1I M-BJM^P M#[KB:/)CJP$$!S_"=SP5S0&-?>:!"& 2P0G:'=D>C>ILWI.>.PW-EUY7W*A4 M2RF=%\$>&D"S>9HT PGDX@+.:@'JOO1FTO'&'FO#,#*\U$PAI'B%ZRMQBNV$ MPBN(QZ1HHIGM,A]P55W4>DHVCL &H\,O0#EY\VE#BM(L:96< 6-K6!W!E2DDOG5[VL"NX MI '>(S%"\!'DQK&BO6!T\(#5 ]R?ENF.D;=G6SHGIN9>[QHEY/8P%%89= MS!!J;])#KI=(RYP:N-UVCR&+J=:D#9XSR QCV%62TT/ T\HOU]@A1:FJUN$2 MK A^68'3HHKU 8VF\@F'651!2 S-_@B6P3TCZ&(.P& *;Y/C)90R=P!X=P%3 MP7$?"# *)0H[HO3+MN@78G(GMNI9\N?:N#_?BH^\LB3CI$0C$K$TT<9$RIL4 M9:658SV:#BBM<22*OI2M$5])01_+;Z7E(+$@R./B3O7#U+Z'6A?- M<78\__&0F_)+S:!T;R2C2ILJ[&):)AW/,ZE,*,"KE0'(NV.A_2US2XXBDI^BA"8Z2"JV @BCY#EJHKKX"3B< \2A#X O0:6$0[WN. M-:%>U6$/*$25ZNV AH2WP@B$ M4%LLZB:Z693-DOHT!K&\K!=S;IRBT&V4_H<'#=3&-3%5#DS.C8P:GL( N18 M@8KG)5?)?4K'&X;P2.A&X*%)(B:2!%PPR5UM"PR"1=KZYC^(R_#SUD:,77&( MWK)D/T66."9((FW&J#8+3-Y?S"0"NNQ+VDK6YA*>WO+B@I++<$=-9RM@<1VD M1/7T6WTW4R@3F,%D70THD@:@87&:B+ MJ!Q)#8%2*]*X2G]#5JPI'6$[/>UP>(X9&-IBHUN!ET3C\G?IG=1^:+]]].64 M(Q'ZC* ZP..$MJ(56'+@Q)' Q4;D-';:68@1*0V.IL%L(>\7I;B/Z2DP42Z! M/X$=#2B$KG'*![$#BT.AYGT@F*'""NQ4=ZFO*>SA&#:^=8 M;YTX+E/)#23#(,XFH&\TS:/@:?QP:O7_P+D;W!%C@V3'=^4'.Y@(8":DJ5T>.R32P/NHN[JO, MJH55FX'2JT 0?SB7NL%W[./-!OP1Q5[%37*JE-T&3J?3S)M$GNN%UW]]+=@# MGQ/3190QZH9TW23X\>P-4O% .(U-@J=@%.U/'*1H<:Q\*^PE:S7_FCJS=RMO M;RFFD@E0Y #E\EA M;K^,A@N'&=\]GA$,H371X9?)A.'QYLA!G[0Q%=M&C3ZQXU;(X^75>F<'O\], M5-9CEQGR#%I8"E50G@S8AZ^!_ HN8! -M;@0CO4U&NNG:J:':X UU^/EP](J MF7N( IHI^'6N\!P-64T1)$79F%#LPA# M'5!;;7(6P\W444!FZH]4"[79F#S&5%F,/KH@-]?VJA/81GF7,<<'EK+?[V"IE =#CXH_.E+B!O"D]4-DXF?B$ M!9T-4UK15$3C.(,%*5B*&++TU/ MN-$+W*J_["XWN?5^**D8AB,SO]8P/8G=.'#@3ALA<+]8C(_=M[>(352O7,[F M"R P43J_$4M6@7CJ0@KQ1U4NOWP%^IC74%I](;=HB2XO+IS@_I+K0@R.ZOX5 M:K!>#-W7\@)?;CV;'^OY)R&X9'RLYY^$X)*YC&6\D<6< Z(OCE/RI18OR:3"/,_=X95V%7)AU<52$_SVL,9_+PXX><+TMB=?:;NY__$:SU*HQ#2?\:,Y?*7G' MD?>/V4!>^=@KGN]>\D],M\*Q$@(/!ZO MQUF6J933D]S=3)_Q=L?'5I:91"GY^P8>O>U22U,D[*,>IK;!T8(F4U%?LK,( M2.#CSZEBZ@% "%Z@?4)VZJ?'>[OU:N4H3>HGU>S,:.#?()UXX_;CP/S%-Q8? M#=7#R:O5BI02#K/%MW,B1_8L?D^;#'SFD_96CL^. MQGZ):2+\\BM0$_!NC\_YO//)[RA,3ECM<-8"C8A%NQ@WG&+Y+-Y+DAP._ 5W M"+Z2@U^*58@>4>%_>/GS\/)+O^OES\GGGO]>4:[IF$,,Y',=OVMMCS-A@_DA MC0;F8)/4=^4O-_GUG1MY7Z\ZD2MQE?W8P:!P=UD(^K>5KYW+7.7+Y?5YHW]> MO+*^NJ<#9^=GV[$J=XVUDZM:XVCGX.RDLIH[_\?Q/]UW]L1^VV^L71?6?[.,]RN\/OM>,>N.X^#5_>.'6![,9>YNO7I0K@R[[>NOM_6S4_NR M?.">N5]^N(<_!\/+XN67ZK>CH_U&;[\07.W[1]V&$WSQ+G=\Z^=QYTN]U[T] M/!M4#O>-^A?;;/SX9W^G<^($NQ?BG[.+VQWKU+TNK';;WF&W:ES_4[OVO2_, M+?W38';K54Y+W]U76NRS0"[&[?FGP87$8%(+#_/&EL7)QN,)W/K7;Z]75TZ]'[/A'Y;PR MN-N[6CVM'-^UR]5B_Z12N%KUBUZANG]UXNU],R]RQ=N?U^R.L\.3H;/N_'-7 MKW<;NVL_>JL'^[?EKZQ0^=FQSOS.U=IMQS\H!Z7<];&]OE,]&.:-RN?/:FG_ M'U!+ 0(4 Q0 ( "= 3U:=PW"%% 0 !D0 1 " 0 M !A96AA+3(P,C,P,C$T+GAS9%!+ 0(4 Q0 ( "= 3U;I5SB6'@D !9I M 5 " 4,$ !A96AA+3(P,C,P,C$T7V1E9BYX;6Q02P$" M% ,4 " G0$]6>\/3?"T, +D0 %0 @ &4#0 865H M82TR,#(S,#(Q-%]L86(N>&UL4$L! A0#% @ )T!/5L$RJ+!H" L&, M !4 ( !]!D &%E:&$M,C R,S R,31?<')E+GAM;%!+ 0(4 M Q0 ( "= 3U;;G\,EN"8 %37 * " 8\B !E>#DY M+3$N:'1M4$L! A0#% @ )T!/5C7%DD/3'@ 0<$ L H ( !;TD &9O0$ &MH $! end